These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15829378)

  • 1. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
    Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
    Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
    Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
    Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T; Toi M; Tominaga T
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
    J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
    Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease.
    Enjoji M; Yamaguchi K; Nakashima M; Ohta S; Kotoh K; Fukushima M; Kuniyoshi M; Tanaka M; Nakamuta M; Watanabe T; Nawata H
    Liver Int; 2004 Aug; 24(4):330-4. PubMed ID: 15287856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
    Nakae H; Narita K; Endo S
    J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
    Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
    Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients.
    Ulukaya E; Acilan C; Yilmaz M; Yilmaztepe-Oral A; Ari F; Zik B; Ursavas A; Tokullugil AH
    Cell Biochem Funct; 2010 Oct; 28(7):565-70. PubMed ID: 20941746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum pseudouridine as a biochemical marker in small cell lung cancer.
    Tamura S; Fujioka H; Nakano T; Hada T; Higashino K
    Cancer Res; 1987 Nov; 47(22):6138-41. PubMed ID: 2822241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
    Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
    Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
    Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
    Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic chemotherapy for brain metastasis from small cell lung cancer].
    Tanaka H; Takifuji N; Masuda N; Takada M; Kudo S; Nakagawa K; Matsui K; Ito K; Kusunoki Y; Fukuoka M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Apr; 31(4):492-7. PubMed ID: 8390590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of tumor markers in the management of small cell lung cancer].
    Ariyoshi Y
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
    Satchell AC; Barnetson RS; Halliday GM
    Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
    Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
    Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.